Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) FCF Margin (2022 - 2025)

Oramed Pharmaceuticals' FCF Margin history spans 4 years, with the latest figure at 176.1% for Q1 2025.

  • For Q1 2025, FCF Margin fell 42576.0% year-over-year to 176.1%; the TTM value through Dec 2025 reached 308.4%, changed N/A, while the annual FY2025 figure was 457.7%, 144598.0% down from the prior year.
  • FCF Margin reached 176.1% in Q1 2025 per ORMP's latest filing, up from 795.4% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 249.66% in Q1 2024 to a low of 1377.18% in Q1 2022.
  • Average FCF Margin over 4 years is 654.52%, with a median of 795.4% recorded in 2024.
  • Peak YoY movement for FCF Margin: soared 111273bps in 2024, then tumbled -42576bps in 2025.
  • A 4-year view of FCF Margin shows it stood at 925.88% in 2022, then surged by 57bps to 393.77% in 2023, then crashed by -102bps to 795.4% in 2024, then skyrocketed by 78bps to 176.1% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's FCF Margin are 176.1% (Q1 2025), 795.4% (Q2 2024), and 249.66% (Q1 2024).